dual glp-1/glucagon receptor agonists Targeting GLP-1, GIP & GCG in Obesity and Type 2 Diabetes Research Frontiers | GLP-1 Receptor Agonists:

CBS News medical correspondent Dr

Learn what research reveals about GLP-1 effects on energy expenditure.

Individuals should consult their clinicians regarding diagnosis or treatment decisions

Purpose of Review This review will summarize the most contemporary trials for glucagon-like peptide 1 receptor agonists (GLP1-RA) and sodium-glucose cotransporter 2 inhibitors (SGLT2-i) and present guidance on management and recommendations on adjunctive tapering of insulin in patients with insulin-dependent diabetes mellitus, which we term de-insulinization. Recent Findings GLP1-RA and SGLT2-i are the principal classes of diabetes medications evidencing cardiovascular benefit

Overview of GLP-1 Analogue Drugs: Brands, Companies & Clinical Uses GLP-1 analogues have transformed the treatment landscape for Type 2 Diabetes and obesity management offering better glycemic control, cardiovascular benefits, and effective weight loss

Obesity is a growing epidemic that affects millions of people worldwide, leading to serious health complications such as heart disease, diabetes, and certain cancers